**Ingrid Holm, M.D., M.P.H.,** is a professor of pediatrics at Harvard Medical School (HMS), faculty in the Division of Genetics and Genomics and the Division of Endocrinology at Boston Children's Hospital (BCH), and faculty at the HMS Center for Bioethics. She conducts empirical, mixed-methods research to study the impact of returning genomic information. She was co-investigator of the BCH/Brigham and Women's Hospital (BWH) U19 BabySeq project. She is currently co-principal investigator (PI) with BWH's Dr. Robert Green on the BabySeq2 project, a U01 funded by the National Center for Advancing Translational Sciences that builds on the first BabySeq project to explore the impacts of conducting genome sequencing and returning results for newborns of diverse backgrounds. Since 2012, Dr. Holm has been a member of the National Human Genome Research Institute–funded Electronic Medical Records and Genomics (eMERGE) Network. In eMERGE Phase II, she co-led a study of patient perspectives on broad consent in biobanking. In eMERGE Phase III, she was PI of an R01 to conduct interviews and a survey of health care providers across eMERGE Phase III to understand the impact of receiving actionable genomic results on their patients enrolled in eMERGE.
Dr. Holm's other research interest is in rare diseases. She is the Associate Director of Dr. Green's Program on Sudden Unexpected Death in Pediatrics (SUDP), where she leads studies to identify genetic contributions to SUDP, and she is a member of the HMS Undiagnosed Disease Network. She is a pediatric geneticist with clinical focus on bone diseases and disorders of sex development.